& Knudsen, L
Artificial Intelligence may allow for more accurate personalisation of therapy to predict the optimum cocktail of mono agonist therapies based on the genetics and metabolomics of an individual and may quicken the process of drug development [70, 71]
Raufmans years of studying animal toxins led to the uncovering of exendin-4 and eventual production of type 2 diabetes drug Byettaand its a breakthrough that kick-started the entire GLP-1 drug industry
Conclusions Despite recent advances in obesity pharmacotherapies, the need for improvements in medication efficacy, whilst minimising adverse effects, remains
Tirzepatide (Mounjaro, Zepbound, compounded) Tirzepatide dual GIP/GLP-1 mechanism produces robust weight loss and glycemic control, but the shorter half-life means slightly less flexibility in timing
If you experience any suspected side effects, you can report them through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)